Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.
Anti-vascular endothelial growth factor (VEGF)
Biologics
Development
Neovascular age-related macular degeneration (nAMD)
Retinal disease
VEGF-C
VEGF-D
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
received:
04
03
2024
accepted:
16
05
2024
medline:
2
6
2024
pubmed:
2
6
2024
entrez:
1
6
2024
Statut:
aheadofprint
Résumé
The development of treatments targeting the vascular endothelial growth factor (VEGF) signaling pathways have traditionally been firstly investigated in oncology and then advanced into retinal disease indications. Members of the VEGF family of endogenous ligands and their respective receptors play a central role in vasculogenesis and angiogenesis during both development and physiological homeostasis. They can also play a pathogenic role in cancer and retinal diseases. Therapeutic approaches have mostly focused on targeting VEGF-A signaling; however, research has shown that VEGF-C and VEGF-D signaling pathways are also important to the disease pathogenesis of tumors and retinal diseases. This review highlights the important therapeutic advances and the remaining unmet need for improved therapies targeting additional mechanisms beyond VEGF-A. Additionally, it provides an overview of alternative VEGF-C and VEGF-D signaling involvement in both health and disease, highlighting their key contributions in the multifactorial pathophysiology of retinal disease including neovascular age-related macular degeneration (nAMD). Strategies for targeting VEGF-C/-D signaling pathways will also be reviewed, with an emphasis on agents currently being developed for the treatment of nAMD.
Identifiants
pubmed: 38824253
doi: 10.1007/s40123-024-00973-4
pii: 10.1007/s40123-024-00973-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–64. https://doi.org/10.1016/j.cell.2019.01.021 .
doi: 10.1016/j.cell.2019.01.021
pubmed: 30849371
pmcid: 6410740
Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65(3):550–63. https://doi.org/10.1016/j.cardiores.2004.12.002 .
doi: 10.1016/j.cardiores.2004.12.002
pubmed: 15664381
Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–9. https://doi.org/10.2147/vhrm.2006.2.3.213 .
doi: 10.2147/vhrm.2006.2.3.213
pubmed: 17326328
pmcid: 1993983
Uemura A, Fruttiger M, D’Amore PA, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84:100954. https://doi.org/10.1016/j.preteyeres.2021.100954 .
doi: 10.1016/j.preteyeres.2021.100954
pubmed: 33640465
pmcid: 8385046
Sastry A, Ryu C, Jiang X, Ameri H. Visual outcomes in eyes with neovascular glaucoma and anterior segment neovascularization without glaucoma. Am J Ophthalmol. 2022;236:1–11. https://doi.org/10.1016/j.ajo.2021.09.006 .
doi: 10.1016/j.ajo.2021.09.006
pubmed: 34562418
Ishibazawa A, Nagaoka T, Yokota H, et al. Characteristics of retinal neovascularization in proliferative diabetic retinopathy imaged by optical coherence tomography angiography. Investig Ophthalmol Vis Sci. 2016;57(14):6247–55. https://doi.org/10.1167/iovs.16-20210 .
doi: 10.1167/iovs.16-20210
Tang Y, Shi Y, Fan Z. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy. Front Endocrinol (Lausanne). 2023;14:1102361. https://doi.org/10.3389/fendo.2023.1102361 .
doi: 10.3389/fendo.2023.1102361
pubmed: 36755912
Bhattacharya R, Fan F, Wang R, et al. Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion. Br J Cancer. 2017;117(6):848–55. https://doi.org/10.1038/bjc.2017.238 .
doi: 10.1038/bjc.2017.238
pubmed: 28742793
pmcid: 5589988
Yang F, Tang X, Riquelme E, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011;71(16):5512–21. https://doi.org/10.1158/0008-5472.CAN-10-2614 .
doi: 10.1158/0008-5472.CAN-10-2614
pubmed: 21724587
pmcid: 3159530
Fogli S, Del Re M, Rofi E, et al. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Lond). 2018;32(6):1010–20. https://doi.org/10.1038/s41433-018-0021-7 .
doi: 10.1038/s41433-018-0021-7
pubmed: 29398697
Fearnley GW, Odell AF, Latham AM, et al. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. Mol Biol Cell. 2014;25(16):2509–21. https://doi.org/10.1091/mbc.E14-05-0962 .
doi: 10.1091/mbc.E14-05-0962
pubmed: 24966171
pmcid: 4142621
Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403. https://doi.org/10.1038/nrd.2015.17 .
doi: 10.1038/nrd.2015.17
pubmed: 26775688
Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell. 2005;7(2):121–7. https://doi.org/10.1016/j.ccr.2005.01.017 .
doi: 10.1016/j.ccr.2005.01.017
pubmed: 15710325
Anisimov A, Alitalo A, Korpisalo P, et al. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 2009;104(11):1302–12. https://doi.org/10.1161/CIRCRESAHA.109.197830 .
doi: 10.1161/CIRCRESAHA.109.197830
pubmed: 19443835
pmcid: 2776655
Sun Z, Li X, Massena S, et al. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J Exp Med. 2012;209(7):1363–77. https://doi.org/10.1084/jem.20111343 .
doi: 10.1084/jem.20111343
pubmed: 22689825
pmcid: 3405501
Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94(12):1823–32. https://doi.org/10.1038/sj.bjc.6603176 .
doi: 10.1038/sj.bjc.6603176
pubmed: 16773076
pmcid: 2361355
Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006;53(1):91–6. https://doi.org/10.1016/j.lungcan.2006.02.009 .
doi: 10.1016/j.lungcan.2006.02.009
pubmed: 16697074
Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001;61(14):5407–14.
pubmed: 11454684
Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer. 2003;98(10):2125–32. https://doi.org/10.1002/cncr.11764 .
doi: 10.1002/cncr.11764
pubmed: 14601081
Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113(5):1032–42. https://doi.org/10.1002/cncr.23678 .
doi: 10.1002/cncr.23678
pubmed: 18618497
Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80(1):98–106. https://doi.org/10.1002/(sici)1097-0142(19970701)80:1%3c98::aid-cncr13%3e3.0.co;2-a .
doi: 10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a
pubmed: 9210714
Dakowicz D, Zajkowska M, Mroczko B. Relationship between VEGF family members, their receptors and cell death in the neoplastic transformation of colorectal cancer. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23063375 .
doi: 10.3390/ijms23063375
pubmed: 35328794
pmcid: 8952321
Yanase M, Kato K, Yoshizawa K, et al. Prognostic value of vascular endothelial growth factors A and C in oral squamous cell carcinoma. J Oral Pathol Med. 2014;43(7):514–20. https://doi.org/10.1111/jop.12167 .
doi: 10.1111/jop.12167
pubmed: 24762199
Michaelsen SR, Staberg M, Pedersen H, et al. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro Oncol. 2018;20(11):1462–74. https://doi.org/10.1093/neuonc/noy103 .
doi: 10.1093/neuonc/noy103
pubmed: 29939339
pmcid: 6176801
Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer. 2011;104(8):1270–7. https://doi.org/10.1038/bjc.2011.81 .
doi: 10.1038/bjc.2011.81
pubmed: 21407219
pmcid: 3078594
Grau S, Thorsteinsdottir J, von Baumgarten L, et al. Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol. 2011;104(1):103–12. https://doi.org/10.1007/s11060-010-0480-6 .
doi: 10.1007/s11060-010-0480-6
pubmed: 21308397
Li D, Xie K, Ding G, et al. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett. 2014;346(1):45–52. https://doi.org/10.1016/j.canlet.2013.12.004 .
doi: 10.1016/j.canlet.2013.12.004
pubmed: 24333721
Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8(10):e77117. https://doi.org/10.1371/journal.pone.0077117 .
doi: 10.1371/journal.pone.0077117
pubmed: 24143206
pmcid: 3797099
Moffat BA, Chen M, Kariaapper MS, et al. Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res. 2006;12(5):1525–32. https://doi.org/10.1158/1078-0432.CCR-05-1408 .
doi: 10.1158/1078-0432.CCR-05-1408
pubmed: 16533777
Cabral T, Lima LH, Mello LGM, et al. Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. Ophthalmol Retina. 2018;2(1):31–7. https://doi.org/10.1016/j.oret.2017.04.004 .
doi: 10.1016/j.oret.2017.04.004
pubmed: 29376143
pmcid: 5783314
Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull. 2007;30(4):633–7. https://doi.org/10.1248/bpb.30.633 .
doi: 10.1248/bpb.30.633
pubmed: 17409493
Stacker SA, Achen MG. Emerging roles for VEGF-D in human disease. Biomolecules. 2018. https://doi.org/10.3390/biom8010001 .
doi: 10.3390/biom8010001
pubmed: 29300337
pmcid: 5871970
Korhonen A, Gucciardo E, Lehti K, Loukovaara S. Proliferative diabetic retinopathy transcriptomes reveal angiogenesis, anti-angiogenic therapy escape mechanisms, fibrosis and lymphatic involvement. Sci Rep. 2021;11(1):18810. https://doi.org/10.1038/s41598-021-97970-5 .
doi: 10.1038/s41598-021-97970-5
pubmed: 34552123
pmcid: 8458546
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515–26. https://doi.org/10.1056/NEJMra1208129 .
doi: 10.1056/NEJMra1208129
pubmed: 23268666
pmcid: 3695731
Ikeda Y, Yonemitsu Y, Onimaru M, et al. The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium. Exp Eye Res. 2006;83(5):1031–40. https://doi.org/10.1016/j.exer.2006.05.007 .
doi: 10.1016/j.exer.2006.05.007
pubmed: 16842779
Nagineni CN, Kommineni VK, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol. 2012;227(1):116–26. https://doi.org/10.1002/jcp.22708 .
doi: 10.1002/jcp.22708
pubmed: 21374591
Lashkari KM, Ma J, Teague GC, Arroyo J. Expression of VEGF-C, VEGF-D and their cognate receptors in experimental choroidal neovascularization and clinical AMD. Investig Ophthalmol Vis Sci. 2013;54(15):4999–4999.
Zhou H, Zhao X, Yuan M, Chen Y. Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients. BMC Ophthalmol. 2020;20(1):15. https://doi.org/10.1186/s12886-019-1278-8 .
doi: 10.1186/s12886-019-1278-8
pubmed: 31914968
pmcid: 6950800
Joukov V, Kumar V, Sorsa T, et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem. 1998;273(12):6599–602. https://doi.org/10.1074/jbc.273.12.6599 .
doi: 10.1074/jbc.273.12.6599
pubmed: 9506953
Cao R, Eriksson A, Kubo H, et al. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res. 2004;94(5):664–70. https://doi.org/10.1161/01.RES.0000118600.91698.BB .
doi: 10.1161/01.RES.0000118600.91698.BB
pubmed: 14739162
Sun D, Nakao S, Xie F, et al. Molecular imaging reveals elevated VEGFR-2 expression in retinal capillaries in diabetes: a novel biomarker for early diagnosis. FASEB J. 2014;28(9):3942–51. https://doi.org/10.1096/fj.14-251934 .
doi: 10.1096/fj.14-251934
pubmed: 24903276
pmcid: 4139900
Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Investig Ophthalmol Vis Sci. 2002;43(3):849–57.
Zhao B, Smith G, Cai J, Ma A, Boulton M. Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2. Br J Ophthalmol. 2007;91(4):538–45. https://doi.org/10.1136/bjo.2006.101543 .
doi: 10.1136/bjo.2006.101543
pubmed: 16943230
Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21(2):154–65. https://doi.org/10.1016/j.ceb.2008.12.012 .
doi: 10.1016/j.ceb.2008.12.012
pubmed: 19230644
Tammela T, Zarkada G, Nurmi H, et al. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol. 2011;13(10):1202–13. https://doi.org/10.1038/ncb2331 .
doi: 10.1038/ncb2331
pubmed: 21909098
pmcid: 3261765
Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454(7204):656–60. https://doi.org/10.1038/nature07083 .
doi: 10.1038/nature07083
pubmed: 18594512
Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999;86(11):2406–12.
doi: 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.0.CO;2-E
pubmed: 10590384
Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA. 1998;95(24):14389–94. https://doi.org/10.1073/pnas.95.24.14389 .
doi: 10.1073/pnas.95.24.14389
pubmed: 9826710
pmcid: 24383
Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998;95(2):548–53. https://doi.org/10.1073/pnas.95.2.548 .
doi: 10.1073/pnas.95.2.548
pubmed: 9435229
pmcid: 18457
Singh NK, Kotla S, Kumar R, Rao GN. Cyclic AMP response element binding protein mediates pathological retinal neovascularization via modulating DLL4-NOTCH1 signaling. EBioMedicine. 2015;2(11):1767–84. https://doi.org/10.1016/j.ebiom.2015.09.042 .
doi: 10.1016/j.ebiom.2015.09.042
pubmed: 26870802
pmcid: 4740322
Rissanen TT, Markkanen JE, Gruchala M, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92(10):1098–106. https://doi.org/10.1161/01.RES.0000073584.46059.E3 .
doi: 10.1161/01.RES.0000073584.46059.E3
pubmed: 12714562
Lashkari KM, Ma J, Teague GC, Guo C, Baldwin ME. VEGF-C and VEGF-D blockade by VGX-300 inhibits choroidal neovascularization and leakage in a mouse model of wet AMD. Investig Ophthalmol Vis Sci. 2014;55:1823.
Turunen T, Hua A, Shatos M, et al. VEGF-C and VEGF-D inhibition by VGX-300 effectively reduces leukocyte adhesion and vascular leakage in the STZ-rat model of diabetic retinal edema. Investig Ophthalmol Vis Sci. 2019;60:3667.
Alitalo AK, Proulx ST, Karaman S, et al. VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis. Cancer Res. 2013;73(14):4212–21. https://doi.org/10.1158/0008-5472.CAN-12-4539 .
doi: 10.1158/0008-5472.CAN-12-4539
pubmed: 23695550
Shibata MA, Shibata E, Tanaka Y, Shiraoka C, Kondo Y. Soluble Vegfr3 gene therapy suppresses multi-organ metastasis in a mouse mammary cancer model. Cancer Sci. 2020;111(8):2837–49. https://doi.org/10.1111/cas.14531 .
doi: 10.1111/cas.14531
pubmed: 32539229
pmcid: 7419054
Yang H, Kim C, Kim MJ, et al. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer. 2011;10:36. https://doi.org/10.1186/1476-4598-10-36 .
doi: 10.1186/1476-4598-10-36
pubmed: 21481239
pmcid: 3080348
Dumond A, Montemagno C, Vial V, Grepin R, Pages G. Anti-vascular endothelial growth factor C antibodies efficiently inhibit the growth of experimental clear cell renal cell carcinomas. Cells. 2021. https://doi.org/10.3390/cells10051222 .
doi: 10.3390/cells10051222
pubmed: 34943948
pmcid: 8699794
Saif MW, Knost JA, Chiorean EG, et al. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer Chemother Pharmacol. 2016;78(4):815–24. https://doi.org/10.1007/s00280-016-3134-3 .
doi: 10.1007/s00280-016-3134-3
pubmed: 27566701
Hajrasouliha AR, Funaki T, Sadrai Z, et al. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Investig Ophthalmol Vis Sci. 2012;53(3):1244–50. https://doi.org/10.1167/iovs.11-8668 .
doi: 10.1167/iovs.11-8668
Falchook GS, Goldman JW, Desai J, et al. A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors. J Clin Oncol. 2014;32(15 suppl):2524.
doi: 10.1200/jco.2014.32.15_suppl.2524
Ramucirumab Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf . 21 Aug 2023.
Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023;22(6):476–95. https://doi.org/10.1038/s41573-023-00671-z .
doi: 10.1038/s41573-023-00671-z
pubmed: 37041221
Chen MH, Lu SN, Chen CH, et al. How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers? Cancers (Basel). 2021. https://doi.org/10.3390/cancers13143536 .
doi: 10.3390/cancers13143536
pubmed: 35008356
pmcid: 8750103
sanofi-aventis. Zaltrap Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125418s045lbl.pdf . Accessed 4 May 2024.
Lau DK, Mencel J, Chau I. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf. 2022;21(5):589–97. https://doi.org/10.1080/14740338.2022.2008905 .
doi: 10.1080/14740338.2022.2008905
pubmed: 34986714
Patel SA, Nilsson MB, Le X, et al. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–9. https://doi.org/10.1158/1078-0432.CCR-22-1366 .
doi: 10.1158/1078-0432.CCR-22-1366
pubmed: 35969170
pmcid: 10274152
Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J Hematol Oncol. 2020;13(1):143. https://doi.org/10.1186/s13045-020-00977-0 .
doi: 10.1186/s13045-020-00977-0
pubmed: 33109256
pmcid: 7590700
Qin S, Li A, Yi M, et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12(1):27. https://doi.org/10.1186/s13045-019-0718-5 .
doi: 10.1186/s13045-019-0718-5
pubmed: 30866992
pmcid: 6417086
American Macular Degeneration Foundation. Dry vs wet age-related macular degeneration. https://www.macular.org/about-macular-degeneration/what-is-macular-degeneration/types/dry-vs-wet-macular-degeneration .
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116. https://doi.org/10.1016/S2214-109X(13)70145-1 .
doi: 10.1016/S2214-109X(13)70145-1
pubmed: 25104651
Mitchell P, Liew G, Gopinath B, Wong T. Age-related macular degeneration. Lancet. 2018;392(10153):1147–59. https://doi.org/10.1016/S0140-6736(18)31550-2 .
doi: 10.1016/S0140-6736(18)31550-2
pubmed: 30303083
Flores R, Carneiro A, Vieira M, Tenreiro S, Seabra MC. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica. 2021;244(6):495–511. https://doi.org/10.1159/000517520 .
doi: 10.1159/000517520
pubmed: 34130290
Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9(1):62–79. https://doi.org/10.1016/j.gendis.2021.02.009 .
doi: 10.1016/j.gendis.2021.02.009
pubmed: 35005108
Wolf AT, Harris A, Oddone F, et al. Disease progression pathways of wet AMD: opportunities for new target discovery. Expert Opin Ther Targets. 2022;26(1):5–12. https://doi.org/10.1080/14728222.2022.2030706 .
doi: 10.1080/14728222.2022.2030706
pubmed: 35060431
pmcid: 8915198
Eichenbaum D. Visual outcomes in wet AMD: can we do better? https://ophthalmology360.com/retina/visual-outcomes-in-wet-amd-can-we-do-better/ .
Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Dev Ther. 2016;10:1857–67. https://doi.org/10.2147/DDDT.S97653 .
doi: 10.2147/DDDT.S97653
Jackson TL, Slakter J, Buyse M, et al. A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration. Ophthalmology. 2023;130(6):588–97. https://doi.org/10.1016/j.ophtha.2023.02.001 .
doi: 10.1016/j.ophtha.2023.02.001
pubmed: 36754174
Opthea reports positive phase 2a trial results of OPT-302 in diabetic macular edema. https://www.biospace.com/article/releases/opthea-reports-positive-phase-2a-trial-results-of-opt-302-in-diabetic-macular-edema/ . Accessed 4 May 2024.
Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration Preferred Practice Pattern®. Ophthalmology. 2020;127(1):P1–65. https://doi.org/10.1016/j.ophtha.2019.09.024 .
doi: 10.1016/j.ophtha.2019.09.024
pubmed: 31757502
Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–40. https://doi.org/10.1016/S0140-6736(22)00010-1 .
doi: 10.1016/S0140-6736(22)00010-1
pubmed: 35085502
Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and-extend for diabetic macular edema: 2-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2023. https://doi.org/10.1016/j.ophtha.2023.12.026 .
doi: 10.1016/j.ophtha.2023.12.026
pubmed: 38160880
pmcid: 10408192
Patel, P, De Salvo G, Lotery A, et al. Real-world use of faricimab to treat nAMD patients in the UK (FARWIDE study). In: ASRS Annual Meeting, Seattle (2023).
Gale RP, Peto T, Talks J, et al. Real-world use of faricimab to treat DME patients in the UK (FARWIDE study). In: ASRS Annual Meeting, Seattle (2023).
Baumal CR. Wet age-related macular degeneration: treatment advances to reduce the injection burden. Am J Manag Care. 2020;26(5):S103–11. https://doi.org/10.37765/ajmc.2020.43435 .
doi: 10.37765/ajmc.2020.43435
pubmed: 32479026
Zhou P, Zheng S, Wang E, Men P, Zhai S. Conbercept for treatment of neovascular age-related macular degeneration and visual impairment due to diabetic macular edema or pathologic myopia choroidal neovascularization: a systematic review and meta-analysis. Front Pharmacol. 2021;12: 696201. https://doi.org/10.3389/fphar.2021.696201 .
doi: 10.3389/fphar.2021.696201
pubmed: 34712132
pmcid: 8546330
Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133. https://doi.org/10.1186/s12967-023-03937-7 .
doi: 10.1186/s12967-023-03937-7
pubmed: 36810060
pmcid: 9942398
Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963–76. https://doi.org/10.1016/j.ophtha.2019.12.031 .
doi: 10.1016/j.ophtha.2019.12.031
pubmed: 32107066
Coherus BioSciences Inc., Cimerli: highlights of prescribing information. https://www.cimerli.com/pdf/prescribing-information.pdf . Accessed 4 May 2024.
Biogen Inc. Byooviz: highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761202s000lbl.pdf . Accessed 4 May 2024.
Lim JI. An update on the anti-vegf biosimilar pipeline. https://www.reviewofophthalmology.com/article/an-update-on-the-antivegf-biosimilar-pipeline . Accessed 4 May 2024.
Jeremias S. European Commission approves first aflibercept biosimilar. https://www.centerforbiosimilars.com/view/european-commission-approves-first-aflibercept-biosimilar . Accessed 4 May 2024.
European Medicines Agency. Yesafili: summary of product characteristics. https://ec.europa.eu/health/documents/community-register/2023/20230915160213/anx_160213_en.pdf . Accessed 4 May 2024.
Kodjikian L, Decullier E, Souied EH, et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol. 2014;252(10):1529–37. https://doi.org/10.1007/s00417-014-2764-6 .
doi: 10.1007/s00417-014-2764-6
pubmed: 25142373
pmcid: 4180904
Lotery A, Griner R, Ferreira A, Milnes F, Dugel P. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye (Lond). 2017;31(12):1697–706. https://doi.org/10.1038/eye.2017.143 .
doi: 10.1038/eye.2017.143
pubmed: 28731052
Luksa D, Heinke A, Michalska-Malecka K. Two year study of aflibercept and ranibizumab intravitreal therapy in patients with wet AMD. Medicina (Kaunas). 2021. https://doi.org/10.3390/medicina57121293 .
doi: 10.3390/medicina57121293
pubmed: 34946238
Bressler NM, Beaulieu WT, Maguire MG, et al. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in Protocol T. Am J Ophthalmol. 2018;195:93–100. https://doi.org/10.1016/j.ajo.2018.07.030 .
doi: 10.1016/j.ajo.2018.07.030
pubmed: 30077569
pmcid: 6648655
Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr Opin Ophthalmol. 2017;28(6):636–43. https://doi.org/10.1097/ICU.0000000000000424 .
doi: 10.1097/ICU.0000000000000424
pubmed: 28837425
Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85. https://doi.org/10.1007/s10456-011-9249-6 .
doi: 10.1007/s10456-011-9249-6
pubmed: 22302382
pmcid: 3338918
Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–9. https://doi.org/10.1016/j.ophtha.2016.02.022 .
doi: 10.1016/j.ophtha.2016.02.022
pubmed: 26935357
Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. https://doi.org/10.1016/j.ophtha.2019.04.017 .
doi: 10.1016/j.ophtha.2019.04.017
pubmed: 30986442
Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141–52. https://doi.org/10.1016/S0140-6736(24)00063-1 .
doi: 10.1016/S0140-6736(24)00063-1
pubmed: 38461841
Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295–307. https://doi.org/10.1016/j.ophtha.2021.09.016 .
doi: 10.1016/j.ophtha.2021.09.016
pubmed: 34597713
Genentech. Voluntary recall of the SUSVIMO™ Ocular Implant. https://www.gene.com/download/pdf/Susvimo_DHCP_Important_Prescribing_Information_2022-10-18.pdf . Accessed 4 May 2024.
Sharma A, Khanani AM, Parachuri N, et al. Port delivery system with ranibizumab (Susvimo) recall—what does it mean to the retina specialists. Int J Retina Vitreous. 2023;9(1):6. https://doi.org/10.1186/s40942-023-00446-z .
doi: 10.1186/s40942-023-00446-z
pubmed: 36717931
pmcid: 9887765
Finocchio L, Zeppieri M, Gabai A, et al. Recent developments in gene therapy for neovascular age-related macular degeneration: a review. Biomedicines. 2023;11(12):3221. https://doi.org/10.3390/biomedicines11123221 .
doi: 10.3390/biomedicines11123221
pubmed: 38137442
pmcid: 10740940
Khanani AM, Boyer DS, Wykoff CC, et al. Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. EClinicalMedicine. 2023;67:102394. https://doi.org/10.1016/j.eclinm.2023.102394 .
doi: 10.1016/j.eclinm.2023.102394
pubmed: 38152412
pmcid: 10751837
Adverum, Press release: Adverum Biotechnologies announces positive preliminary efficacy and safety data from LUNA phase 2 trial of ixo-vec in patients with wet AMD. https://investors.adverum.com/news/news-details/2024/Adverum-Biotechnologies-Announces-Positive-Preliminary-Efficacy-and-Safety-Data-from-LUNA-Phase-2-Trial-of-Ixo-vec-in-Patients-with-Wet-AMD/default.aspx . Accessed 4 May 2024.
Campochiaro PA, Avery R, Brown DM, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024;403(10436):1563–73. https://doi.org/10.1016/S0140-6736(24)00310-6 .
doi: 10.1016/S0140-6736(24)00310-6
pubmed: 38554726
Hussain RM, Shaukat BA, Ciulla LM, Berrocal AM, Sridhar J. Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration. Drug Des Dev Ther. 2021;21(15):2653–65. https://doi.org/10.2147/DDDT.S295223 .
doi: 10.2147/DDDT.S295223
Dugel PU, Boyer DS, Antoszyk AN, et al. Phase 1 study of OPT-302 inhibition of vascular endothelial growth factors C and D for neovascular age-related macular degeneration. Ophthalmol Retina. 2020;4(3):250–63. https://doi.org/10.1016/j.oret.2019.10.008 .
doi: 10.1016/j.oret.2019.10.008
pubmed: 31924544
Del Amo EM, Hammid A, Tausch M, et al. Ocular metabolism and distribution of drugs in the rabbit eye: quantitative assessment after intracameral and intravitreal administrations. Int J Pharm. 2022;613:121361. https://doi.org/10.1016/j.ijpharm.2021.121361 .
doi: 10.1016/j.ijpharm.2021.121361
pubmed: 34896561
Do DV, Rhoades W, Nguyen QD. Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration. Retina. 2020;40(4):643–7. https://doi.org/10.1097/IAE.0000000000002566 .
doi: 10.1097/IAE.0000000000002566
pubmed: 31145389
Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154(4):682–686682. https://doi.org/10.1016/j.ajo.2012.03.047 .
doi: 10.1016/j.ajo.2012.03.047
pubmed: 22818800
Struble C, Tester A, Gerometta M, et al. Ocular distribution and pharmacokinetics of 125I-OPT302 and 125I-aflibercept (EYLEA) following intravitreal administration to pigmented rabbits. Acta Ophthalmol. 2014;92:s253.
doi: 10.1111/j.1755-3768.2014.F056.x
Teague GC, Ma J, Johnson W, et al. Expression of VEGF-A, VEGF-C, VEGF-D and soluble receptors in clinical age-related macular degeneration. Investig Ophthalmol Vis Sci. 2016;57:3698.
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe). ClinicalTrials.gov Identifier NCT04757610. Updated March 28, 2024. https://clinicaltrials.gov/study/NCT04757610 . Accessed May 4, 2024.
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST). ClinicalTrials.gov Identifier NCT04757636. Updated March 28, 2024. https://clinicaltrials.gov/study/NCT04757636 . Accessed May 4, 2024.
Das N, Chaurasia S, Singh RP. A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration. Expert OpinEmerg Drugs. 2023;28(3):203–11. https://doi.org/10.1080/14728214.2023.2259790 .
doi: 10.1080/14728214.2023.2259790
Khanani AM, Regillo CD, Wykoff CC, et al. Sustained-release tyrosine kinase inhibitors for the treatment of nAMD. Retinal Physician. 2022;19:22–5.
Hutton D. Clearside Biomedical opens enrollment in ODYSSEY phase 2b clinical trial of CLS-AX in wet AMD. Ophthalmology Times. 2023. https://www.ophthalmologytimes.com/view/clearside-biomedical-opens-enrollment-in-odyssey-phase-2b-clinical-trial-of-cls-ax-in-wet-amd .
Hutton D. Angiogenesis 2023: Ocular Therapeutix announces data from phase 1 clinical trial evaluating OTX-TKI for treatment of wet AMD. Ophthalmol Retina. 2023. https://www.ophthalmologytimes.com/view/angiogenesis-2023-ocular-therapeutix-announces-data-from-phase-1-clinical-trial-evaluating-otx-tki-for-treatment-of-wet-amd .
EyePoint Pharmaceuticals completes enrollment in phase 2 PAVIA clinical trial of EYP-1901 in non-proliferative diabetic retinopathy. https://www.biospace.com/article/releases/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy/#:~:text=About%20EYP%2D1901,vorolanib%2C%20a%20tyrosine%20kinase%20inhibitor .
EyePoint Pharmaceuticals. Press release: EyePoint Pharmaceuticals announces positive topline data from the phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints. https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-positive-topline-data-phase-2 . Accessed 4 May 2024.
Marcus DM, Hu A, Barakat M, et al. Safety and tolerability study of suprachoroidal injection CLS-AX in neovascular AMD patients with persistent activity following anti-VEGF therapy (OASIS, NCT04626128; Extension Study NCT NCT05131646). Investig Ophthalmol Vis Sci. 2023;64(8):728.
Wong JG, Chang A, Guymer RH, et al. Phase 1 study of an intravitreal axitinib hydrogel-based implant for the treatment of neovascular age-related macular degeneration (nAMD). Investig Ophthalmol Vis Sci. 2021;62(8):218.
Moshfeghi AA, Khanani AM, Eichenbaum DA, et al. U.S. Phase 1 study of intravitreal axitinib implant (OTX-TKI) for neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci. 2023;64(8):936.
Glance Editorial Team. FDA amends SPA for Ocular Therapeutix phase 3 wet AMD trial. Glance by Eyes On Eyecare. https://glance.eyesoneyecare.com/stories/2024-01-29/fda-amends-spa-for-ocular-therapeutix-phase-3-wet-amd-trial/ . Accessed Jan 28, 2024.
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration. ClinicalTrials.gov Identifier NCT06223958. Updated February 13, 2024. https://clinicaltrials.gov/study/NCT06223958 . Accessed May 4, 2024.
Boskabadi SJ, Dashti A, Karevan S, Kargar-Soleimanabad S, Salehifar E. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: a narrative review. J Oncol Pharm Pract. 2023. https://doi.org/10.1177/10781552231174790 .
doi: 10.1177/10781552231174790
pubmed: 37170573
Jackson TL, Boyer D, Brown DM, et al. Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study. JAMA Ophthalmol. 2017;135(7):761–7. https://doi.org/10.1001/jamaophthalmol.2017.1571 .
doi: 10.1001/jamaophthalmol.2017.1571
pubmed: 28570723
pmcid: 5710207
Baker SD, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther. 2009;85(2):208–11. https://doi.org/10.1038/clpt.2008.242 .
doi: 10.1038/clpt.2008.242
pubmed: 19092780
Arepalli S, Kaiser PK. Pipeline therapies for neovascular age related macular degeneration. Int J Retina Vitreous. 2021;7(1):55. https://doi.org/10.1186/s40942-021-00325-5 .
doi: 10.1186/s40942-021-00325-5
pubmed: 34598731
pmcid: 8485527
4DMT. Press release: 4DMT presents positive interim data from intravitreal 4D-150 phase 1/2 PRISM clinical trial in patients with wet AMD at ARVO. 2023. https://4dmt.gcs-web.com/news-releases/news-release-details/4dmt-presents-positive-interim-data-intravitreal-4d-150-phase-12 .
Hutton, D, 4DMT received FDA Regenerative Medicine Advanced Therapy designation for 4D-150 genetic medicine for intravitreal treatment of wet AMD. 2023. https://www.ophthalmologytimes.com/view/4dmt-receives-fda-regenerative-medicine-advanced-therapy-designation-for-4d-150-genetic-medicine-for-intravitreal-treatment-of-wet-amd .
Hutton, D, 4DMT presents positive interim data from Phase 2 PRISM clinical trial of intravitreal 4D-150 for wet AMD. Ophthalmology Times. https://www.ophthalmologytimes.com/view/4dmt-presents-positive-interim-data-from-phase-2-prism-clinical-trial-of-intravitreal-4d-150-for-wet-amd . Accessed 4 May 2024.
Innovent. Press release: Innovent announces first participant dosed in phase 1 clinical study of IBI333 (VEGF-A/VEGF-C bispecific fusion protein) in patients with neovascular age-related macular degeneration. https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-phase-1-clinical-study-of-ibi333-vegf-avegf-c-bispecific-fusion-protein-in-patients-with-neovascular-age-related-macular-degeneration-301756600.html . Accessed 4 May 2024.